Funding
The German venture capital firm PolyTechnos has announced that its portfolio company Cappella, Inc. has closed a third financing round of $17.3 million. New investors included Fountain Healthcare Partners, Mitsui & Co. Venture Partners, and Enterprise Ireland. Current investors including PolyTechnos Venture-Partners and ACT Venture Capital.
Cappella, is developing devices for the repair of coronary artery lesions in sidebranch and bifurcation locations. It was recently granted CE mark approval for its first device in Europe, and the new money will enable it to start marketing the product.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
